BioRegenxBRGX FCF Margin % is 6.34% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 666 Healthcare Providers & Services companies, BioRegenx ranks worse than 54.65% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioRegenx's Free Cash Flow for the
three
months ended in Mar. 2026 was $0.03 Mil. BioRegenx's Revenue for the
three
months ended in Mar. 2026 was $0.43 Mil. Therefore, BioRegenx's FCF Margin % for the quarter that ended in Mar. 2026 was 6.34%.
The historical rank and industry rank for BioRegenx's FCF Margin % or its related term are showing as below:
BRGX'
s FCF Margin % Range Over the Past 10 Years
Min: -154.76 Med: -35.66 Max: 1.59
Current: 1.59
During the past 12 years, the highest FCF Margin % of BioRegenx was 1.59%. The lowest was -154.76%. And the median was -35.66%.
BRGX's FCF Margin % is ranked worse than 54.65% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 3.095
vs BRGX: 1.59
BioRegenx FCF Margin % Related Terms
BioRegenx FCF Margin % Historical Data
* Premium members only.
The historical data trend for BioRegenx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, BioRegenx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRegenx FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioRegenx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BioRegenx's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRegenx (BRGX) has a FCF Margin % of 6.34% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioRegenx and its competitors. According to the industry distribution chart, BioRegenx ranks #364 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 54.7%.
Is BioRegenx's FCF Margin % too high?
BioRegenx's current FCF Margin % is 6.34%. The Healthcare Providers & Services industry median FCF Margin % is 3.10. BioRegenx's value of 6.34% is 104.8% above this industry median. Based on the distribution chart, BioRegenx ranks #364 out of 666 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does BioRegenx's FCF Margin % compare to VYND and ACON?
According to the Healthcare Providers & Services industry distribution chart, BioRegenx ranks #364 out of 666 companies for FCF Margin %. This places BioRegenx in the lower half of its industry. The industry median FCF Margin % is 3.10. BioRegenx's value of 6.34% is 104.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.10, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRegenx's current FCF Margin % of 6.34% is 104.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioRegenx and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRegenx's current FCF Margin % is 6.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRegenx stock overvalued right now?
Based on GuruFocus' analysis, BioRegenx (BRGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 24% below its estimated fair value. The current FCF Margin % is 6.34% and 104.8% above the Healthcare Providers & Services industry median of 3.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BioRegenx (BRGX), the current FCF Margin % is 6.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. It focuses on commercialization of its patented technologies in its field.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRGX has been successfully added to your 